Docket Number:10A-990415
Inventor:Han-Chang Wu, Ruei-Min Lu
IP Status:US 9,150,655、TW I523867、CN103415619B、EP2611928, JP5955322
Abstract:
Overexpression of c-Met, hepatocyte growth factor receptor, has been found in various cancer types, and related to cancer metastasis, angiogenesis and drug-resistance. We identified human single chain Fv (scFv) that specifically bound to c-Met protein and c-Met-expressing cancer cells. The strong tumor fluoresencent signals provided by the scFv-conjugated quantum dots in vivo demonstrate the potential of this scFv in tumor targeting. The scFv-mediated delivery significantly improved therapeutic efficacy of chemotherapeutic drugs in human lung cancer xenograft mice.
Fields of Application:
- Tumor diagnosis
- Targeting therapy and antiangiogenic therapy for tumor
- In vivo tumor imaging
Advantages when compared to the existing technologies:
- The anti-c-Met antibodies are entirely human origin, but not from mouse or chimera. This will evade human anti-mouse antibody (HAMA) immune response, and should be less immunogenicity.
- The anti-c-Met scFv can carry chemotherapeutic drugs to c-Met-expressing tumor tissue in vivo, so that this strategy enables to improve therapeutic index compared to conventional chemotherapy.
- Targeting to c-Met can achieve multiple anti-cancer functions such as cytotoxicity for cancer cells, tumor vasculatures, and metastatic and drug-resistant cancer cells.
- The scFv can be engineered to intact human IgG, which is useful to develop therapeutic antibody for cancer treatment.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
